Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Radius: A Phase 2 Randomized Trial Investigating Standard of Care ± Midostaurin after Allogeneic Stem Cell Transplant in FLT3 -ITD-Mutated AML

Richard Thomas T. Maziarz, MD, Mrinal M. Patnaik, MDMBBS, Bart L Scott, MD, Sanjay R. Mohan, MD MSCI, Abhinav Deol, MD, Scott D. Rowley, MD, Dennis Kim, MD, Kelly Haines, Gaetano J Bonifacio, MD, Patrice Rine, Das Purkayastha, Hugo F. Fernandez, MD

Blood (2018) 132 (Supplement 1): 662.

https://doi.org/10.1182/blood-2018-99-113582

Published: 2018

Journal Articles

Dasatinib Induced Reversible Nephrotic Range Proteinuria Occurs More Frequently Compared to Other Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia

Ali Alahmari, MD, Jeffrey H. Lipton, MD PhD, Dennis Kim, MD

Blood (2017) 130 (Supplement 1): 2880.

https://doi.org/10.1182/blood.V130.Suppl_1.2880.2880

Published: 2017

Journal Articles

Morphological Subtype According to the FAB Classification Correlates with Molecular Subtype Using Genomic Risk Classification Based on Somatic Mutation Profiles in Normal Karyotype AML

Blood (2017) 130 (Supplement 1): 5075.

https://doi.org/10.1182/blood.V130.Suppl_1.5075.5075

Published: 2017

Journal Articles

Dynamics of Methylation Profiling in Response to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia

Shun Liao, Taehyung Kim, MSc, Hyeoung-Joon Kim, Jae-Sook Ahn, Jaehyuk Choi, Yeo-Kyeoung Kim, Yoon-Sang Kim, Seung-Shin Lee, MD, Zhaolei Zhang, PhD, Dennis Kim, MD

Blood (2017) 130 (Supplement 1): 1599.

https://doi.org/10.1182/blood.V130.Suppl_1.1599.1599

Published: 2017

Journal Articles

Pre-Transplant Pulmonary Function Test Parameters of FEF50% (Forced expiratory flow at 50% of forced vital capacity) and RV (residual volume) in Combination Can Predict the Risk for Development of Lung Gvhd after Allogeneic Transplantation

Wilson Lam, MD, Arjun Datt Law, MBBS, MD DM, Fotios V. Michelis, MD PhD, Santhosh Thyagu, MD, Auro Viswabandya, MDMDcine,DM Clinical Hematology, Jeffrey H. Lipton, MD PhD, Hans A. Messner, MD PhD, Theodore Marras, MD MSc, Shikha Mittoo, MD MHS, Dennis Kim, MD

Blood (2017) 130 (Supplement 1): 1973.

https://doi.org/10.1182/blood.V130.Suppl_1.1973.1973

Published: 2017

Journal Articles

Interim Results of the Canadian Tyrosine Kinase Inhibitor Discontinuation Trial for 2 nd Attempt of Treatment Free Remission: Treatment Free Remission Accomplished By Dasatinib (TRAD)

Dennis Kim, MD, Isabelle Bence-Bruckler, Donna L Forrest, MD, Lynn Savoie, Stephen Couban, MDBSc, Lambert Busque, MD, Robert Delage, Pierre Laneuville, MD FRCPC, Elena Liew, MDBSc,FRCPC, Anargyros Xenocostas, MD, Kristjan Paulson, MD, Suzanne Kamel-Reid, Jeffrey H. Lipton, PhD MD FRCPC, Brian Leber, MD

Blood (2017) 130 (Supplement 1): 1622.

https://doi.org/10.1182/blood.V130.Suppl_1.1622.1622

Published: 2017

Journal Articles

Evidence of Effect Modification of Graft-Versus-Leukemia Effect of Cytomegalovirus By Alemtuzumab in Myeloid Malignancies Undergoing Unrelated Donor Transplantation

Mohamed Shanavas, MD FRACP, FRCPA, Jieun Uhm, MD, Naheed Alam, MBBS,MD, Eshetu G Atenafu, MSc, John Kuruvilla, MD FRCPC, Jeffrey H. Lipton, MD PhD, Hans A. Messner, MD PhD, Matthew Seftel, MRCP, FRCPC, MPH, Vikas Gupta, MD MRCP, FRCPath, Dennis Kim, MD PhD

Blood (2014) 124 (21): 5927.

https://doi.org/10.1182/blood.V124.21.5927.5927

Published: 2014

Journal Articles

Outcomes of Allogeneic Hematopoietic Cell Transplantation In Aplastic Anemia Using Intermediate Dose Alemtuzumab Based-Conditioning

Nada Hamad, MBBS Hons, FRACP, FRCPA, Ryan Del Bel, B.Math, Hans A. Messner, M.D./Ph.D, Dennis Kim, MD, John Kuruvilla, MD, Jeffrey H. Lipton, MD, PhD, Jieun Uhm, MD, Wei Xu, Vikas Gupta, MD, FRCP, FRCPath

Blood (2013) 122 (21): 2044.

https://doi.org/10.1182/blood.V122.21.2044.2044

Published: 2013

Journal Articles

Risk Model Incorporating Donor IL6 and ifng Genotype and Gut Gvhd Can Discriminate High Risk Patients For Steroid Refractory Acute Gvhd

Naheed Alam, MBBS, Eshetu G Atenafu, MSc, Wei Xu, Ph.D., Jieun Uhm, MD, Vikas Gupta, MD, FRCP, FRCPath, John Kuruvilla, MD, Hans A. Messner, MD, PhD, Jeffrey H. Lipton, MD, PhD, Dennis Kim, MD, PhD

Blood (2013) 122 (21): 4613.

https://doi.org/10.1182/blood.V122.21.4613.4613

Published: 2013

Journal Articles

The Risk Of BK Virus Haemorrhagic Cystitis After Allogeneic Hematopoietic Stem Cell Transplantation Is Increased With Myeloablative Conditioning, CMV Viremia and Acute Gvhd

Jieun Uhm, MD, Nada Hamad, MBBS Hons, FRACP, FRCPA, Mohamed Shanavas, MD, FRACP, FRCPA, Fotios V. Michelis, MD, PhD, Vikas Gupta, MD, FRCP, FRCPath, John Kuruvilla, MD, FRCPC, Hans A. Messner, MD, PhD, Jeffrey H. Lipton, MD, PhD, Dennis Kim, MD

Blood (2013) 122 (21): 3289.

https://doi.org/10.1182/blood.V122.21.3289.3289

Published: 2013

Journal Articles

Mycophenolate Compared to Methotrexate As Part of Cyclosporine Based-GVHD Prophylaxis Does Not Affect Transplant Outcomes, Reduces Organ Specific Acute And Chronic GVHD, but Increases The Risk of CMV Viremia In Matched Related Donor Peripheral Blood Stem Cell Transplantation

Nada Hamad, MBBS Hons, FRACP, FRCPA, Mohamed Shanavas, MD, FRACP, FRCPA, Fotios V. Michelis, MD, PhD, Jieun Uhm, MD, Vikas Gupta, MD, FRCP, FRCPath, John Kuruvilla, MD, Jeffrey H. Lipton, MD, PhD, Hans A. Messner, M.D./Ph.D, Dennis Kim, MD

Blood (2013) 122 (21): 3303.

https://doi.org/10.1182/blood.V122.21.3303.3303

Published: 2013

Journal Articles

Impact of Myeloablative Versus Reduced Intensity Conditioning Regimens on Early Lymphocyte Recovery and Its Impact on Transplant Outcomes after Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients with Hematologic Malignancies.

Dong Hwan (Dennis) Kim, MD, PhD, Gizelle Popradi, MD, John Kuruvilla, MD, Vikas Gupta, MD, Mark Minden, MD, PhD, Jeffrey H. Lipton, MD, PhD, Hans A. Messner, MD, PhD

Blood (2007) 110 (11): 5039.

https://doi.org/10.1182/blood.V110.11.5039.5039

Published: 2007

Journal Articles

Late Onset Eosinophilia (beyond Day 100), Rather Than Early Onset Eosinophilia, Has a Significant Prognostic Impact on Transplant Outcomes after Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT).

Dong Hwan (Dennis) Kim, MD, PhD, Gizelle Popradi, MD, John Kuruvilla, MD, Vikas Gupta, MD, Mark Minden, MD, PhD, Hans A. Messner, MD, PhD, Jeffrey H. Lipton, MD, PhD

Blood (2007) 110 (11): 1062.

https://doi.org/10.1182/blood.V110.11.1062.1062

Published: 2007

Journal Articles

Early Recovery of Absolute Lymphocyte Count (ALC) Is a Predictor of Long-Term Outcome Following Related Allogeneic Peripheral Blood Stem Cell Transplantation in Adults with AML/MDS.

Gizelle Popradi, MD, Dong Hwan (Dennis) Kim, MD/PhD, John Kuruvilla, MD, Vikas Gupta, MD, Mark Minden, MD/PhD, Jeffrey H. Lipton, MD/PhD, Hans A. Messner, MD/PhD

Blood (2007) 110 (11): 1102.

https://doi.org/10.1182/blood.V110.11.1102.1102

Published: 2007

Journal Articles

No Significance of Derivative Chromosome 9 Deletion on the Clearance Kinetics of BCR/ABL Fusion Transcripts, Cytogenetic or Molecular Response, Loss of Response or Treatment Failure to Imatinib Mesylate Therapy for Chronic Myeloid Leukemia.

Dong Hwan (Dennis) Kim, MD, PhD, Lakshmi Sriharsha, Suzanne Kamel-Reid, MD, PhD, Hong Chang, MD, Hans Messner, MD, PhD, Jeffrey Lipton, MD, PhD

Blood (2007) 110 (11): 1950.

https://doi.org/10.1182/blood.V110.11.1950.1950

Published: 2007

Journal Articles

Clinical Relevance of a Pharmacogenetic Approach Using Multiple Candidate Gene Polymorphisms To Predict Response and Resistance to Imatinib Mesylate Therapy in Chronic Myeloid Leukemia.

Dong Hwan (Dennis) Kim, MD, PhD, Lakshmi Sriharsha, Wei Xu, Suzanne Kamel-Reid, Xiangdong Liu, Katherine Siminovitch, Hans Messner, Jeffrey Lipton

Blood (2007) 110 (11): 737.

https://doi.org/10.1182/blood.V110.11.737.737

Published: 2007

NARROW

Radius: A Phase 2 Randomized Trial Investigating Standard of Care ± Midostaurin after Allogeneic Stem Cell Transplant in FLT3 -ITD-Mutated AML

Dasatinib Induced Reversible Nephrotic Range Proteinuria Occurs More Frequently Compared to Other Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia

Morphological Subtype According to the FAB Classification Correlates with Molecular Subtype Using Genomic Risk Classification Based on Somatic Mutation Profiles in Normal Karyotype AML

Dynamics of Methylation Profiling in Response to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia

Pre-Transplant Pulmonary Function Test Parameters of FEF50% (Forced expiratory flow at 50% of forced vital capacity) and RV (residual volume) in Combination Can Predict the Risk for Development of Lung Gvhd after Allogeneic Transplantation

Interim Results of the Canadian Tyrosine Kinase Inhibitor Discontinuation Trial for 2 nd Attempt of Treatment Free Remission: Treatment Free Remission Accomplished By Dasatinib (TRAD)

Evidence of Effect Modification of Graft-Versus-Leukemia Effect of Cytomegalovirus By Alemtuzumab in Myeloid Malignancies Undergoing Unrelated Donor Transplantation

Outcomes of Allogeneic Hematopoietic Cell Transplantation In Aplastic Anemia Using Intermediate Dose Alemtuzumab Based-Conditioning

Risk Model Incorporating Donor IL6 and ifng Genotype and Gut Gvhd Can Discriminate High Risk Patients For Steroid Refractory Acute Gvhd

The Risk Of BK Virus Haemorrhagic Cystitis After Allogeneic Hematopoietic Stem Cell Transplantation Is Increased With Myeloablative Conditioning, CMV Viremia and Acute Gvhd

Mycophenolate Compared to Methotrexate As Part of Cyclosporine Based-GVHD Prophylaxis Does Not Affect Transplant Outcomes, Reduces Organ Specific Acute And Chronic GVHD, but Increases The Risk of CMV Viremia In Matched Related Donor Peripheral Blood Stem Cell Transplantation

Impact of Myeloablative Versus Reduced Intensity Conditioning Regimens on Early Lymphocyte Recovery and Its Impact on Transplant Outcomes after Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients with Hematologic Malignancies.

Late Onset Eosinophilia (beyond Day 100), Rather Than Early Onset Eosinophilia, Has a Significant Prognostic Impact on Transplant Outcomes after Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT).

Early Recovery of Absolute Lymphocyte Count (ALC) Is a Predictor of Long-Term Outcome Following Related Allogeneic Peripheral Blood Stem Cell Transplantation in Adults with AML/MDS.

No Significance of Derivative Chromosome 9 Deletion on the Clearance Kinetics of BCR/ABL Fusion Transcripts, Cytogenetic or Molecular Response, Loss of Response or Treatment Failure to Imatinib Mesylate Therapy for Chronic Myeloid Leukemia.

Clinical Relevance of a Pharmacogenetic Approach Using Multiple Candidate Gene Polymorphisms To Predict Response and Resistance to Imatinib Mesylate Therapy in Chronic Myeloid Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only